▶ 調査レポート

世界のパーキンソン病における脳深部刺激療法(DBS)市場(~2027):製品別、エンドユーザー別、地域別

• 英文タイトル:Deep Brain Stimulation in Parkinson’s Disease Market Research Report by Product, End-user, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。世界のパーキンソン病における脳深部刺激療法(DBS)市場(~2027):製品別、エンドユーザー別、地域別 / Deep Brain Stimulation in Parkinson’s Disease Market Research Report by Product, End-user, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2303H162資料のイメージです。• レポートコード:MRC2303H162
• 出版社/出版日:360iResearch / 2022年10月11日
• レポート形態:英語、PDF、249ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の当調査レポートでは、2021年に815.87百万ドルであった世界のパーキンソン病における脳深部刺激療法(DBS)市場規模が2022年に936.05百万ドルとなり、今後は年平均14.98%成長して2027年までに1,885.68百万ドルに達すると予測しています。当書は、パーキンソン病における脳深部刺激療法(DBS)の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(デュアルチャンネル、シングルチャンネル)分析、エンドユーザー別(外来手術センター、病院、神経科クリニック、研究センター)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報など、以下の構成でまとめております。なお、当書には、Abbott Laboratories、Aleva Neurotherapeutics SA、Allergan Plc、Beijing PINS Medical Co. Ltd、Boston Scientific Corporation、Cyberonics, Inc、Fisher Wallace、Functional Neuromodulation Ltd、LIVANOVA PLC、Medtronic PLCなどの企業情報が含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界のパーキンソン病における脳深部刺激療法(DBS)市場規模:製品別
- デュアルチャンネルの市場規模
- シングルチャンネルの市場規模
・世界のパーキンソン病における脳深部刺激療法(DBS)市場規模:エンドユーザー別
- 外来手術センターにおける市場規模
- 病院における市場規模
- 神経科クリニックにおける市場規模
- 研究センターにおける市場規模
・世界のパーキンソン病における脳深部刺激療法(DBS)市場規模:地域別
- 南北アメリカのパーキンソン病における脳深部刺激療法(DBS)市場規模
アメリカのパーキンソン病における脳深部刺激療法(DBS)市場規模
カナダのパーキンソン病における脳深部刺激療法(DBS)市場規模
ブラジルのパーキンソン病における脳深部刺激療法(DBS)市場規模
...
- アジア太平洋のパーキンソン病における脳深部刺激療法(DBS)市場規模
日本のパーキンソン病における脳深部刺激療法(DBS)市場規模
中国のパーキンソン病における脳深部刺激療法(DBS)市場規模
インドのパーキンソン病における脳深部刺激療法(DBS)市場規模
韓国のパーキンソン病における脳深部刺激療法(DBS)市場規模
台湾のパーキンソン病における脳深部刺激療法(DBS)市場規模
...
- ヨーロッパ/中東/アフリカのパーキンソン病における脳深部刺激療法(DBS)市場規模
イギリスのパーキンソン病における脳深部刺激療法(DBS)市場規模
ドイツのパーキンソン病における脳深部刺激療法(DBS)市場規模
フランスのパーキンソン病における脳深部刺激療法(DBS)市場規模
ロシアのパーキンソン病における脳深部刺激療法(DBS)市場規模
...
- その他地域のパーキンソン病における脳深部刺激療法(DBS)市場規模
・競争状況
・企業情報

The Global Deep Brain Stimulation in Parkinson’s Disease Market size was estimated at USD 815.87 million in 2021 and expected to reach USD 936.05 million in 2022, and is projected to grow at a CAGR 14.98% to reach USD 1,885.68 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Deep Brain Stimulation in Parkinson’s Disease to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Dual Channel and Single Channel.

Based on End-user, the market was studied across Ambulatory Surgical Centers, Hospitals, Neurology Clinics, and Research Centers.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Deep Brain Stimulation in Parkinson’s Disease market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Deep Brain Stimulation in Parkinson’s Disease Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Deep Brain Stimulation in Parkinson’s Disease Market, including Abbott Laboratories, Aleva Neurotherapeutics SA, Allergan Plc, Beijing PINS Medical Co. Ltd, Boston Scientific Corporation, Cyberonics, Inc, Fisher Wallace, Functional Neuromodulation Ltd, LIVANOVA PLC, Medtronic PLC, MicroTransponder Inc, Neuronetics Inc., NeuroPace Inc., NeuroSigma, Inc., Nevro Corporation, Nexstim Oy, Renishaw PLC, ReShape Lifesciences, Inc, Synapse Biomedical Inc, and Zynex, Inc.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Deep Brain Stimulation in Parkinson’s Disease Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Deep Brain Stimulation in Parkinson’s Disease Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Deep Brain Stimulation in Parkinson’s Disease Market?
4. What is the competitive strategic window for opportunities in the Global Deep Brain Stimulation in Parkinson’s Disease Market?
5. What are the technology trends and regulatory frameworks in the Global Deep Brain Stimulation in Parkinson’s Disease Market?
6. What is the market share of the leading vendors in the Global Deep Brain Stimulation in Parkinson’s Disease Market?
7. What modes and strategic moves are considered suitable for entering the Global Deep Brain Stimulation in Parkinson’s Disease Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of neurological diseases
5.1.1.2. Rapidly aging population, leading to risk and high prevalence of neurological disorders
5.1.1.3. Rising popularity of minimally invasive procedures
5.1.2. Restraints
5.1.2.1. Complex regulatory framework
5.1.3. Opportunities
5.1.3.1. Increasing technological advancement in devices
5.1.3.2. Surge in neurological R&D
5.1.4. Challenges
5.1.4.1. Risks of deep brain stimulation surgery
5.2. Cumulative Impact of COVID-19

6. Deep Brain Stimulation in Parkinson’s Disease Market, by Product
6.1. Introduction
6.2. Dual Channel
6.3. Single Channel

7. Deep Brain Stimulation in Parkinson’s Disease Market, by End-user
7.1. Introduction
7.2. Ambulatory Surgical Centers
7.3. Hospitals
7.4. Neurology Clinics
7.5. Research Centers

8. Americas Deep Brain Stimulation in Parkinson’s Disease Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Deep Brain Stimulation in Parkinson’s Disease Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Deep Brain Stimulation in Parkinson’s Disease Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbott Laboratories
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Aleva Neurotherapeutics SA
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Allergan Plc
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Beijing PINS Medical Co. Ltd
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Boston Scientific Corporation
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Cyberonics, Inc
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Fisher Wallace
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Functional Neuromodulation Ltd
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. LIVANOVA PLC
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Medtronic PLC
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. MicroTransponder Inc
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Neuronetics Inc.
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. NeuroPace Inc.
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. NeuroSigma, Inc.
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Nevro Corporation
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Nexstim Oy
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Renishaw PLC
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. ReShape Lifesciences, Inc
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Synapse Biomedical Inc
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Zynex, Inc
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing



グローバル市場調査レポート販売サイトを運営しているマーケットリサーチセンター株式会社です。